If you have been reading about Visceral adiposity and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Trelagliptin (trade name Trelaglip, Zafatek) is a pharmaceutical drug used for the treatment of type 2 diabetes (diabetes mellitus).Trelagliptin is an orally active dipeptidyl peptidase (DPP)-4 inhibitor developed by Takeda and approved in Japan and India for the treatment of type 2 diabetes mellitus. Zuventus Healthcare introduced Trelagliptin in India (2025) under the brand name Trelaglip®.
The current understanding of the drying conditions varies between different spray drying configurations and solution contents, but more research is being completed into the determination of what drives each particle shape pathways as future applications in pharmaceutical and industrial areas require better control over specific particle shapes and sizes of their products.
== History and discovery == "Ultraviolet" means "beyond violet" (from Latin ultra, "beyond"), violet being the color of the highest frequencies of visible light. Ultraviolet has a higher frequency (thus a shorter wavelength) than violet light. UV radiation was discovered in February 1801 when the German physicist Johann Wilhelm Ritter observed that invisible rays just beyond the violet end of the visible spectrum darkened silver chloride-soaked paper more quickly than violet light itself. He announced the discovery in a very brief letter to the Annalen der Physik and later called them "(de-)oxidizing rays" (German: de-oxidierende Strahlen) to emphasize chemical reactivity and to distinguish them from "heat rays", discovered the previous year at the other end of the visible spectrum. The simpler term "chemical rays" was adopted soon afterwards, and remained popular throughout the 19th century, although some said that this radiation was entirely different from light (notably John William Draper, who named them "tithonic rays"). The terms "chemical rays" and "heat rays" were eventually dropped in favor of ultraviolet and infrared radiation, respectively. In 1878, the sterilizing effect of short-wavelength light by killing bacteria was discovered. By 1903, the most effective wavelengths were known to be around 250 nm. In 1960, the effect of ultraviolet radiation on DNA was established.
Sources: en.wikipedia.org
NMR spectroscopy has been utilized for the analysis of biological samples since the 1980s, and can be used as an effective technique for the identification and quantification of both known and unknown metabolites. For details on the principles of this technique, see NMR spectroscopy. In pharmacometabolomics analyses, NMR is advantageous because minimal sample preparation is required. Isolated patient samples typically include blood or urine due to their minimally-invasive acquisition, however, other fluid types and solid tissue samples have also been studied with this approach. Due to the minimal preparation of samples before analysis, samples can be potentially fully recovered following NMR analysis (If samples are kept refrigerated to avoid degradation). This permits samples to be repeatedly analysed with extremely high levels of reproducibility, as well as maintaining precious patient samples for an alternative analysis. The high reproducibility and precision of NMR, coupled with relatively fast processing time (greater than 100 samples per day), makes this process a relatively high-throughput form of sample analysis. One disadvantage of this technique is the relatively poor metabolite detection sensitivity compared to MS-based analysis, leading to a requirement for greater initial sample volume. Furthermore, the initial instrument costs are extremely high, for both NMR and MS equipment.
The three substrates of this enzyme are L-aspartic acid, water, and oxidised nicotinamide adenine dinucleotide (NAD+}. Its products are oxaloacetic acid, ammonia, reduced NADH, and a proton. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH2 group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-aspartate:NAD(P)+ oxidoreductase (deaminating). Other names in common use include NAD-dependent aspartate dehydrogenase, NADH2-dependent aspartate dehydrogenase, and NADP+-dependent aspartate dehydrogenase. This enzyme participates in nicotinate and nicotinamide metabolism.
== V == Pablo Valenzuela (b. 1941). Chilean biochemist and biotechnologist at Chiron Corporation (Emeryville, California), known for his genetic studies of hepatitis viruses. Member of the Chilean Academy of Sciences. Ruth van Heyningen (1917–2019). British biochemist at Oxford University, known for her research on the lens and cataracts. Donald Van Slyke (1883–1971). Dutch American biochemist at the Brookhaven National Laboratory noted for the measurement of gas and electrolyte levels in tissues. A unit of measurement for buffering activity, the slyke, is named after him. Member Natl. Acad. Sci. USA. John Craig Venter (1946–2026). American biotechnologist at the J. Craig Venter Institute (Rockville, Maryland), known for human genome sequencing. Member Natl. Acad. Sci. USA. Donald Voet (1938–2023). American biochemist at the University of Pennsylvania known for his textbook Biochemistry. Judith G. Voet (b. 1941). American biochemist at Swarthmore College known for her textbook Biochemistry.
Sources: en.wikipedia.org
After World War I, the victors settled border changes. The Treaty of Saint-Germain of 1919 ruled according to the 1915 London Pact, that the southern part of the Austrian crown land of Tyrol had to be ceded to the Kingdom of Italy, including the territory of the former Trent bishopric, roughly corresponding to the modern-day Trentino, as well as the south of the medieval Tyrol county, the present-day province of South Tyrol. Italy thus took control of the strategically important Alpine water divide at the Brenner Pass and over the south of Tyrol proper with its large German-speaking majority. Since 1949 both parts form the autonomous Italian Trentino-Alto Adige/Südtirol region. The northern part of Tyrol retained by the First Austrian Republic today forms the Austrian State of Tyrol with its East Tyrol exclave. In 1945 following World War II, Austrian attempts and South Tyrolean petitions to reunite South Tyrol with Austria were unsuccessful; Italy retained control. From 1972 onwards, the Italian Republic has granted further autonomy to the Trentino-Alto Adige/Südtirol region.
=== 2000s === 2000: Venezuelan astrophysicist Kathy Vivas presented her discovery of approximately 100 "new and very distant" RR Lyrae stars, providing insight into the structure and history of the Milky Way galaxy. 2000: Russian gynaecologist Galina Savelyeva founded the Department of Obstetrics and Gynaecology at Moscow State University. Savelyeva was one of the first scientists in the world to demonstrate the feasibility of using craniocerebral hypothermia in the treatment of babies born with asphyxia, which formed the basis for the Russian Ministry of Health's order on the primary resuscitation of babies born with asphyxia. 2001: Danish physicist Lene Hau led a Harvard University team who used a Bose–Einstein condensate to slow down a beam of light to about 17 metres per second, then were able to stop a beam completely. 2003: Danish structural chemist and crystallographer Sine Larsen became the first female scientific research director at the European Synchrotron Radiation Facility (ESRF), where she was responsible for research in the fields of structural biology and structural chemistry. 2003: American geophysicist Claudia Alexander oversaw the final stages of Project Galileo, a space exploration mission that ended at the planet Jupiter. 2004: American biologist Linda B. Buck received the Nobel Prize in Physiology or Medicine along with Richard Axel "for their discoveries of odorant receptors and the organization of the olfactory system". 2004: American astrophysicist and radio astronomer Naomi McClure-Griffiths identified a new spiral arm of the Milky Way galaxy.
== Other uses == The ground product can be called masa nixtamalera. In Central American and Mexican cuisine, masa nixtamalera is cooked with water and milk to make a thick, gruel-like beverage called atole. When made with chocolate and sugar, it becomes atole de chocolate. Adding anise and piloncillo to this mixture creates champurrado, a popular breakfast drink.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.